Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer

NCT02930902 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02930902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02930902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
February 20, 2017
Completion date
January 3, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable pancreatic carcinoma, stage i pancreatic cancer ajcc v6 and v7, stage ia pancreatic cancer ajcc v6 and v7, stage ib pancreatic cancer ajcc v6 and v7, stage ii pancreatic cancer ajcc v6 and v7, stage iia pancreatic cancer ajcc v6 and v7, stage iib pancreatic cancer ajcc v6 and v7